Search filters

Filters
Clear All

Phase

  • 15
  • 15
  • 1
  • 14
  • 1
  • 17
  • 4
  • 41
  • 125
  • 48
  • 3
  • 6
  • 116
  • 122
  • 3
  • 1
  • 124

Found 125 Lymphocytic Leukemia, Acute trials

A listing of Lymphocytic Leukemia, Acute medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Gene Transfer for Patients With Sickle Cell Disease Using a Gamma Globin Lentivirus Vector
18 years - 99 years
All genders
Phase 1
This Phase 1/2 study will use a novel therapy, ARU-1801, for Sickle Cell Disease, using gene transfer of recombinant -globin lentivirus (LV) vector. The purpose of this study, which involves research, is to determine whether an experimental procedure called “gene transfer” is safe and effective. If you are interested in …
 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
18 years - 39 years
All genders
Phase 3
Interventional
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
 A Phase 1/2 Open-Label Clinical Trial of TC-110 T Cells in Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL) Or Acute Lymphoblastic Leukemia (ALL)
18 years - 99 years
All genders
Phase 1
The goal of this trial is to evaluate the safety of autologous genetically modified TC-110 T cells in adult patients with aggressive NHL (DLBCL, PMBCL, TFL, MCL), high-risk indolent NHL, or ALL. And to establish the recommended phase 2 dose (RP2D) for the NHL and ALL indications according to the …
 A Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
18 years - 99 years
All genders
Phase 1
Interventional
This study is being done to determine what effects the therapy venetoclax has on acute lymphoblastic leukemia (ALL).This investigational therapy will be added to what is a standard, liposomal vincristine, to treat relapsed ALL.
 UPCC 04717: Phase I  open label  dose-escalation study to evaluate the safety  expansion  persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor)  administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL)
99 years or below
All genders
Phase 1
The main aims of this study are to test the safety of up to 4 different doses of UCART19, and to identify the best dose of UCART19, by measuring what has happened to the leukemia cells at day 28 (28 days after the administration of UCART19), day 84 (84 days …
 Managed Access Program (MAP) to provide access to CTL019  for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
99 years or below
All genders
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
Learn More
Online study
 Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) alone and when co-administered with humanized Anti-CD19 Chimeric Antigen Receptor Redirected T cells (huCART19) In Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
99 years or below
All genders
Phase 1
This is a single center, single arm, open-label Phase 1 study with two cohorts to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
 The Plea Trial(Posterior Wall and Left Atrial Appendage Empiric Electrical Isolation for Non-Paroxysmal Atrial Fibrillation)
18 years - 99 years
All genders
The PLEA trial is designed to test the hypothesis whether posterior wall isolation (PWI) with pulmonary vein isolation (PVI), PWI plus left atrial appendage electrical isolation (LAAEI) with PVI and PWI plus LAAEI plus coronary sinus isolation (CSI) with PVI is superior to the standard approach alone (i.e. PVI alone) …
 LODESTAR: Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes
18 years - 99 years
All genders
Phase 2
This is a Phase 2 multicenter, open-label study evaluating rucaparib as treatment for solid tumors associated with a deleterious mutation in Homologous Recombination Repair (HRR) genes. All patients will be required to have received prior treatment with at least 1 line of life-extending therapy (if available) or have a tumor …
 The Development of a Chatbot to Augment Population Hypertension Management
18 years - 99 years
All genders
The purpose of this study is to design, implement, and evaluate a chatbot to support hypertension management communications between the clinical team who support UPHS' Employee Hypertension Program (EHP) and the patients - employees of UPHS. The study population will include all adult patients who are enrolled in the EHP …
91 - 100 of 125